A composition comprising a pharmaceutically effective amount of a pharmaceutically acceptable benzoate salt of 5-methoxy-N,N-dimethyltryptamine (5MeODMT).

Plant-based medicinal compounds or nutritional supplements in various carrier combinations are described. The carriers can include N-acylated fatty amino acids, penetration enhancers, and/or various other beneficial carriers. The plant-based composition/carrier combinations can create administration benefits.

Methods for treating headache, migraine and related symptoms by administering a CGRP antagonist and a Clostridial derivative are described.

Provided is a fast-dispersing dosage form for oral delivery, wherein the fast-dispersing dosage form includes a rimegepant. Also provided is a method for delivering rimegepant to a subject, wherein the method includes orally administering to the subject a fast-dispersing dosage form including rimegepant.

Provided is a fast-dispersing dosage form for oral delivery, wherein the fast-dispersing dosage form includes a rimegepant. Also provided is a method for delivering rimegepant to a subject, wherein the method includes orally administering to the subject a fast-dispersing dosage form including rimegepant.

The present invention relates to a compound and the application thereof in treating inflammation or inflammation-related diseases, and more specifically to a compound UTLOH combination. Said compound effectively inhibits the level of LPS-induced PGE2 and NO, while effectively treating inflammatory or inflammatory-related diseases.

The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.

The present invention concerns a pharmaceutically acceptable salt of a compound of the following formula (I): H.sub.2N—CH(R.sub.1)—CH.sub.2S—S—CH.sub.2—CH(R.sub.2—CONH—CH(R.sub.3)—COOR.sub.4 (I) and more particularly an acid addition salt thereof, and the compositions comprising the same, for use in the prevention or treatment of trigeminal nerve pain, in particular migraines or trigeminal neuralgia.

The present invention concerns a pharmaceutically acceptable salt of a compound of the following formula (I): H.sub.2N—CH(R.sub.1)—CH.sub.2S—S—CH.sub.2—CH(R.sub.2—CONH—CH(R.sub.3)—COOR.sub.4 (I) and more particularly an acid addition salt thereof, and the compositions comprising the same, for use in the prevention or treatment of trigeminal nerve pain, in particular migraines or trigeminal neuralgia.

The present disclosure is directed to peptide immunogen constructs targeting portions of Pituitary adenylate cyclase-activating polypeptide (PACAP), compositions containing the constructs, antibodies elicited by the constructs, and methods for making and using the constructs and compositions thereof. The disclosed peptide immunogen constructs have more than about 20 amino acids and contain (a) a B cell epitope having about more than about 9 contiguous amino acid residues from the PACAP receptor binding or activation regions of the full-length PACAP protein; (b) a heterologous Th epitope; and (c) an optional heterologous spacer. The disclosed PACAP peptide immunogen constructs stimulate the generation of highly specific antibodies directed PACAP for the prevention and/or treatment of migraine.